Press Release

Red Arrow Therapeutics and ASKA Pharmaceutical Sign Joint ResearchAgreement on Novel Preeclampsia Treatment
TOKYO, March 18, 2024 – ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo/President, Representative Director: Sohta Yamaguchi, hereinafter “ASKA”), a subsidiary of ASKA
Pharmaceutical Holdings Co., Ltd. (TSE:4886, hereinafter “the Company”), and Red Arrow
Therapeutics Inc. (Head Office: Boston, Massachusetts/ CEO: Takuya Miyazaki) announced
today that they have signed a joint research agreement to develop a new treatment forpreeclampsia using advanced nanotechnology. Please see the attached for details.
The impact of this matter on the business performance of the Company for FY2023 will beimmaterial.

Media Contacts
ASKA Pharmaceutical Holdings Co., Ltd.
Corporate Planning Department
Tel: +81-3-5484-8366
Email: kouhou@aska-pharma.co.jp

ASKA Pharmaceutical and Red Arrow Therapeutics Sign Joint Research
Agreement on Novel Preeclampsia Treatment
TOKYO, March 18, 2024 – ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo,Japan/ President, Representative Director: Sohta Yamaguchi) and Red Arrow Therapeutics Inc.
(Head Office: Boston, Massachusetts/ CEO: Takuya Miyazaki) announced today that they havesigned a joint research agreement to develop a new treatment for preeclampsia using advanced
nanotechnology.
A Statement from Takuya Miyazaki, CEO of Red Arrow Therapeutics:"Through this partnership with ASKA Pharmaceutical, we're excited to push the boundaries ofnanomedicine and bring a novel solution to a disease with significant impact on pregnant womenand babies, who are the cornerstones of our future. Our joint effort exemplifies the power ofcombining cutting-edge science with pharmaceutical expertise."
A Statement from Sohta Yamaguchi, President, Representative Director of ASKA
Pharmaceutical:"This alliance with Red Arrow, which is known for its innovative drug delivery technology,enhances our pursuit of novel treatments. Together, we're focused on making significant strides
in maternal healthcare. As a leading company in the field of obstetrics and gynecology, we will
strive to fulfill unmet medical needs."
Since its foundation in 1920, ASKA Pharmaceutical has contributed to patients' well-being,
specializing in the fields of internal medicine, obstetrics and gynecology, and urology as aspecialty pharma.
Established in 2021, Red Arrow Therapeutics aims to deliver the cutting-edge nanomedical
technology developed by Professor Horacio Cabral from the University of Tokyo to patients inneed.
By combining ASKA Pharmaceutical's extensive expertise with Red Arrow Therapeutics' pHsensing drug delivery nanotechnology, the joint research agreement is anticipated to birth agroundbreaking approach to combat preeclampsia, a condition that presents significant risks
during pregnancy.
About Red Arrow Therapeutics Inc.
Emerging from Cabral Lab at the University of Tokyo in 2021, Red Arrow Therapeutics Inc.
develops pH-sensing nanomedicine drug delivery technologies for multiple therapeutic areas
such as oncology. Headquartered in Boston, Massachusetts, the company is committed torealizing cutting-edge technology for patients worldwide.
URL: https://redarrowtx.com/

About ASKA Pharmaceutical Co., Ltd.
Since its foundation in 1920, ASKA has concentrated its management resources in three coreareas of internal medicine, obstetrics and gynecology, and urology, based on its corporate
philosophy: "Contribute toward the improvement of people's health and progress in medicine
through the development of innovative products." Under the Medium-Term Management Plan
2025, ASKA has set a goal to "become a Total Healthcare Company with a Strong Foundation asa Specialty Pharma Company." As a leading company in the obstetrics and gynecology field,
ASKA is committed to contributing to the resolution of women's health issues through its businessactivities.
URL: https://www.aska-pharma.co.jp/english/Inquiries
Red Arrow Therapeutics Inc.
E-mail：rika@redarrowtx.com
ASKA Pharmaceutical Co., Ltd.
Corporate Planning Department
E-mail：kouhou@aska-pharma.co.jp